AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

CNS Stimulants for Adults Age 19 and Above

 A review of written documentation to substantiate a complete, appropriate, and covered diagnosis for both new starts and members currently receiving any CNS stimulant listed below will be required before Prior Authorization approval. <u>Prescribing history alone WILL NOT meet criteria for approval.</u>

MEMBER & PRESCRIBER INFO	RMATION: Authorization may be delayed if incomplete.					
Member Name:						
Member AvMed #:						
Prescriber Name:						
Prescriber Signature: Date:						
Office Contact Name:						
Phone Number:	Fax Number:					
NPI #:						
DRUG INFORMATION: Authorization						
Drug Name/Form/Strength:						
☐ Request is being submitted for BRAND	☐ Request is being submitted for GENERIC					
Dosing Schedule:	Length of Therapy:					
Diagnosis:	ICD Code:					
Weight (if applicable):	Date weight obtained:					
 Will the member be discontinuing a previous medication if approved for requested medical 	ously prescribed central nervous system (CNS) stimulant cation?					
	□ Yes OR □ No					
If yes, please list the medication that will be approval along with the corresponding effective.	be discontinued and the medication that will be initiated upon ective date.					
Medication to be discontinued:	Effective date:					
Medication to be initiated:	Effective date:					

(Continued on next page)

DRUG(S) REQUESTED:	Check applicable drug(s) below. Box(es) must be checked to qualify, or
authorization process will be dela	ayed.

□ Adha		<u> </u>	Adzenys XR-ODT® Adzenys ER® Suspension		amphetamine/ dextroamphetamine (Adderall®)		amphetamine/ dextroamphetamine ER (Adderall XR®)
	etamine ER (Adzenys XR	٥	amphetamine sulfate (Evekeo®)		Azstarys [®]		Cotempla XR/ODT®
□ dexme (Focal	ethylphenidate in®)	۵	dexmethylphenidate ER (Focalin XR®)		dextroamphetamine (Dextrostat®)		dextroamphetamine (ProCentra®)
□ dextre (Zenze	pamphetamine edi [®])		dextroamphetamine ER (Dexedrine Spansule®)		Dyanavel® XR Suspension Dyanavel® XR Chewable Tablets		Evekeo ODT®
□ Jorna	y PM®		methamphetamine (Desoxyn®)	0	methylphenidate ER (Aptensio XR®)		methylphenidate ER (Concerta®)
	v lphenidate TD (Daytrana [®])		methylphenidate ER (Metadate ER [®] / Ritalin SR [®])		methylphenidate (Methylin®/Ritalin®)		methylphenidate LA (Ritalin LA®)
	Iphenidate CD date CD®)		Mydayis [®]		Quillichew® ER		Quillivant XR®
□ Vyvai	1se®		Xelstrym [™] (dextroamphetamine)				
DIAGNOSES: Check applicable diagnosis below with ICD Code and description. For **BINGE EATING DISORDER, obtain BED specific form, found under "Vyvanse (Binge Eating Disorder). **							
□ ADHD/ADD: ICD-9/10: Description:							
*please complete table below and attach/fax any documentation as requested							

*NON-FDA approved indications - submit two (2) peer reviewed clinical studies documenting the safety and efficacy of the specified drug for that particular indication.

(Continued on next page)

T C 41	Name of Diagnosing Prescriber:			Date of Diagnosis:
of th sym _l	e pre otom	escriber, the date of diagnosis, and copies o	f tes	either a child or an adult, please submit the name sting and chart notes detailing signs and he prescribing physician in the table below or as a
d s	etern	nine that criteria have been met (including do g) to make the diagnosis of ADHD?		Manual of Mental Disorders, 5TH Edition and mentation of impairment in more than one major
	ı No			
e E	valua VAI	ation (NOTE: THE PATIENT-SPECIFIC I	DSN ATI	nting scale, patient interview, or psychological M SYMPTOMS, CRITERIA, PSYCHOLOGICAL ING SCALE USED TO MAKE OR VERIFY THE S FORM FOR APPROVAL)
	Ac	dult Self-Report Scale- V1.1		Member Interview
) W	ender Adult ADHD Rating Scale		Psychological Evaluation
	Ot	ther:		
Azs	stary		avel	le for Adhansia XR [®] , Adzenys [®] , Aptensio XR [®] , l [®] XR, Evekeo [®] /Evekeo ODT [®] , Jornay PM [®] , vm [™] , the following criteria MUST be met:
	me	tember must have tried and failed 30 days of the dications — medication trial MUST include a tethylphenidate-based stimulant (verified by continuous).	ın aı	
	Ar	mphetamine-based stimulants: (select all th	at a _l	pply)
		amphetamine-dextroamphetamine IR/ER (g	ene	ric Adderall/Adderall XR®)
		dextroamphetamine IR/SR (generic Dextros	stat®	Procentra®/Zenzedi®/Dexedrine® IR/ER)
		lisdexamfetamine (generic Vyvanse®)		
		insuchamine (generic vyvanse)		
		(ethylphenidate-based stimulants: (select al	l tha	at apply)
		· · · · · · · · · · · · · · · · · · ·		

Please be aware if this request is for a dose that <u>EXCEEDS</u> AvMed Health's Maximum Daily Dosage Limits, a second prior authorization request will need to be submitted for dosage approval. The correct form can be downloaded from https://www.avmed.org/forms/provider/

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

**Use of samples to initiate therapy does not meet step edit/preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *

^{*}Approved by Pharmacy and Therapeutics Committee: 7/17/2014; 1/18/2018; 9/15/2022; 2/16/2023; 7/24/2025; 9/25/2025 REVISED/UPDATED/REFORMATTED: 6/3/2019; 7/17/2019; 8/13/2019; 12/7/2020; 9/10/2021, 11/8/2021; 11/7/2022; 3/2/2023; 7/01/2024; 8/18/2025; 10/24/2025